IPP Bureau
Evonik launches next-generation peptide for biopharma applications
By IPP Bureau - June 02, 2023
One thousand times more soluble than L-cystine at neutral pH
Philips and Masimo introduce advanced monitoring capabilities to Philips high acuity patient monitors
By IPP Bureau - June 02, 2023
The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment
Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options
By IPP Bureau - June 02, 2023
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Merck partners with California-based research group to study catalysis innovation through machine learning
By IPP Bureau - June 02, 2023
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy
By IPP Bureau - June 02, 2023
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Lonza acquires biotech firm Synaffix
By IPP Bureau - June 02, 2023
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Laurus Labs to increase stake in ImmunoACT to 33.86%
By IPP Bureau - June 01, 2023
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
USFDA inspects contract manufacturing facility of Jubilant Pharmova at Montreal Canada
By IPP Bureau - June 01, 2023
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
Lupin receives USFDA approval from Obeticholic Acid Tablets
By IPP Bureau - June 01, 2023
Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).
Honeywell refurbishes PHCs in rural India across three states
By IPP Bureau - June 01, 2023
The project is part of a three-year-long partnership between Honeywell and Americares to strengthen the health infrastructure in rural Maharashtra, Uttarakhand and Haryana
Glenmark sets GHG emission targets for FY2035
By IPP Bureau - June 01, 2023
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
.jpg "HMD supplied 1.75 billion syringes of the total 13.3 billion COVID 19 vaccines administered globally")
HMD supplied 1.75 billion syringes of the total 13.3 billion COVID 19 vaccines administered globally
By IPP Bureau - June 01, 2023
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
Synexa Joins CEPI in advancing global epidemic preparedness and response
By IPP Bureau - May 31, 2023
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData
By IPP Bureau - May 31, 2023
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Concept Medical gets 4th IDE approval from USFDA
By IPP Bureau - May 31, 2023
For the treatment of Superficial Femoral Artery
